US device firm Heartware aims for ASX
07 December, 2004 by Renate KrelleUS venture-capital-backed artificial heart company Heartware is hoping to be the first in what might become a new wave of US firms considering an Australian IPO as an interim financing round, before moving on to a Nasdaq listing.
Industry cries foul over ACCC chicken labelling ruling
07 December, 2004 by Graeme O'NeillThe Australian Consumer and Competition Commission (ACCC), has dismayed Australia's agbiotech community by ruling that chickens fed genetically modified grain cannot be labelled GM-free.
Industry cries foul over ACCC labelling decision
07 December, 2004 by Graeme O'NeillThe Australian Consumer and Competition Commission (ACCC), has dismayed Australia's agbiotech community by ruling that chickens fed genetically modified grain cannot be labelled "GM-free".
Eqitx to raise $1.8 million
07 December, 2004 by Melissa TrudingerMelbourne-based biotech managed investment group EQiTX (ASX: EQX) will ask shareholders to approve a AUD$1.8 million capital raising to provide working capital for its two projects ZingoTX and VacTX.
Peptech to pay shareholders dividend after patent win
06 December, 2004 by Renate KrellePeptech (ASX:PTD) is begrudgingly sharing the booty from its recent legal win, announcing today it would 'reward' shareholders with a dividend of 8 cents per share.
Cellestis gets FDA approval, raises $11m
06 December, 2004 by Melissa TrudingerAustralian immunodiagnostics company Cellestis (ASX:CST) has received approval from the FDA for its second generation QuantiFERON-TB Gold tuberculosis diagnostic test.
Acrux sees opportunity in competitor's FDA hiccup
06 December, 2004 by Melissa TrudingerAcrux (ASX:ACR) CEO Igor Gonda says the failure of Proctor and Gamble (P&G) to gain approval from an FDA advisory panel for its testosterone patch to treat low libido in surgically menopausal women presents a good opportunity for Acrux and its US development partner Vivus to catch up.
Meditech begins second stage of Phase II
06 December, 2004 by Melissa TrudingerMeditech Research (ASX:MTR) has commenced the second stage of its Phase II trial of HyCAMP, its proprietary formulation of chemotherapeutic drug irinotecan in combination with hyaluronic acid.
Proteome Systems chairman sets out company's new course
02 December, 2004 by Renate KrelleProteome Systems (ASX:PXL), once the great hope of the Australian biotech sector, has set a new course towards drug discovery and diagnostics, and away from its traditional identity as an instrument manufacturer -- and is considering selling sections of its business, as well as buying into a drug discovery play, as it changes focus.
New head named for QBF
02 December, 2004 by Renate KrelleNeill Colledge, the senior portfolio manager and head of research for domestic equities at Queensland Investment Corporation (QIC), has replaced Kathryn Radford as CEO of the AUD$100 million Queensland BioCapital Funds (QBF).
Benitec to fight patent claims
02 December, 2004 by Graeme O'NeillBrisbane-based gene therapy company Benitec (ASX:BLT) will continue to defend itself against what it today described as "baseless attacks" on its patent position by US company Nucleonics.
The re-invention game
01 December, 2004 by Graeme O'NeillBig Pharma executives are searching desperately for a way of 'evergreening" the world's most lucrative drugs, the cholesterol-lowering statins, before they run out of patent protection in a few years time.
Pfizer to invest $36m in Aust
30 November, 2004 by Renate KrellePfizer, the world's biggest drugmaker, has earmarked AUD$36.4 million over four years for Australian collaborations.
Stirling reports positive preliminary trial results
30 November, 2004 by Melissa TrudingerStirling Products (ASX: STI) has reported that preliminary results from the trials of its lead product ST810 (R-salbutamol) in pigs indicate significantly higher potency than expected, with economic viability at the lowest dose tested.
Select acquires remainder of subsidiaries
30 November, 2004 by Melissa TrudingerSelect Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.
